GreenLight Biosciences Holdings (NasdaqGM: GRNA)
Health Care · Biotechnology · US
$—
— today · — 1Y
GreenLight Biosciences Holdings (NasdaqGM: GRNA) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores GreenLight Biosciences Holdings across four factors: quality 14/100. Its strongest factor is quality.
GRNA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $10.34M
- P/E
- —
- EPS
- -1.11
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 280
- Next earnings
- —
About GreenLight Biosciences Holdings
GreenLight Biosciences Holdings is a biotechnology firm focused on developing and commercializing ribonucleic acid (RNA) solutions. Its innovative products serve both the human health and agricultural industries. The company's human health portfolio includes mRNA vaccines and various therapeutic treatments, while its agricultural offerings feature RNA-based innovations designed to protect honeybees and defend crops. Established in 2008, GreenLight Biosciences Holdings is based in Medford, Massachusetts.
- ISIN
- US39536G1058
- Founded
- 2008
- Listed since
- Feb 3, 2022
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.